Background. Fetal anemia is common in malarious areas and is a risk factor for infant morbidity and mortality. Malaria during pregnancy may cause decreased cord hemoglobin (Hb) and fetal anemia among newborns. Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is protective against malaria but may also affect hematopoiesis and contribute to fetal anemia.
Malaria during pregnancy continues to contribute to maternal and infant morbidity and mortality in Malawi despite recent scale-up of bed net use and intermittent preventive treatment during pregnancy (IPTp). Pregnant women and children aged <5 years are at highest risk of malaria-related mortality, and malaria during pregnancy is associated with severe maternal anemia and low birth weight, which is due to both restricted fetal growth and preterm birth [1, 2] . However, the impact of malaria on fetal anemia is less well understood. Fetal anemia (cord hemoglobin [Hb] <12.5 g/dL) is common in malarious areas, with a prevalence of approximately 23% in Malawi [3] and up to 93% in Mozambique [4] . Fetal anemia contributes to infant anemia during the first 6 months of life in Malawi and is a risk factor for earlier age at first illness, persistent morbidity episodes, and infant mortality, especially with continued exposure to malaria during infancy [5, 6] .
The evidence for a causal relationship between malaria during pregnancy and fetal anemia has been mixed. Maternal malaria was associated with fetal anemia in 2 studies in Malawi [5, 7] , and an examination of Hb levels in infants reported a sustained impact of malaria on early anemia throughout the first year of life [5] . Another study in Kenya found peripheral parasitemia, but not placental parasitemia, associated with lower Hb at birth [8] . A study in Mozambique and a third smaller study in Malawi did not detect a significant association between malaria and fetal anemia [4, 9] . Similarly, fetal anemia was not associated with peripheral or placental malaria at birth in initial analyses of the data from the study reported here in 1999 [10] . These studies vary in adjustment for covariates, and some include potential mediators, such as maternal anemia, which may bias the effects toward the null.
The World Health Organization (WHO) recommends IPTp such that all pregnant women are given at least 2 doses of sulfadoxine-pyrimethamine (SP) 1 month apart starting in the second trimester [2, 11] . Malawi introduced this intervention in 1993, and coupled with the distribution of bed nets, IPTp has been successful in reducing morbidity and mortality associated with malaria during pregnancy [12] . However, widespread SP resistance in sub-Saharan Africa has potentially reduced the effectiveness of IPTp and has led to concerns that the benefits of SP will be outweighed by net harm. A recent cross-sectional analysis of pregnant women in Tanzania suggested that IPTp with SP was associated with decreased cord Hb and increased odds of fetal anemia. However, detrimental effects of SP on other birth outcomes, such as low birth weight and maternal anemia, were not observed [13] .
Greater understanding of the effect of malaria on fetal anemia and further examination of the relationship between SP and fetal anemia are needed. In this large retrospective study, we estimate the effect of malaria parasitemia at delivery on cord Hb concentration and fetal anemia. We also investigate the relationship between SP use and fetal anemia to determine if SP independently leads to harm.
METHODS

Study Population
The data form a cross-section at delivery of women giving birth in the maternity unit of Queen Elizabeth Central Hospital in Blantyre, Malawi, between August 1997 and August 2006. Queen Elizabeth Central Hospital is an urban hospital with approximately 15 000 deliveries per year. A high proportion of women were primigravidae or had at-risk pregnancies because women with these conditions are encouraged to deliver in the hospital, whereas women are encouraged to deliver at health centers for subsequent pregnancies. Women were eligible if they were in active labor, delivered in the presence of a study team, and had available measurements of cord Hb concentration at delivery. Women were excluded if they were unlikely to deliver during working hours [12] .
Data Collection
Women were enrolled and data were collected as previously described [12] . Briefly, demographic and clinical information was collected by questionnaire. The number of SP doses taken during pregnancy was taken from antenatal clinic cards, which document doses prescribed at the antenatal clinic. To validate antenatal clinic card data, women were asked how many SP doses were taken during pregnancy. Finger-prick blood samples from the mothers for thick blood films were taken to measure peripheral parasitemia and Hb concentration with a HemoCue hemoglobinometer (HemoCueAB). Thick blood films were also prepared with blood from the maternal placental surface and umbilical cord to assess placental and cord parasitemia and cord Hb concentration. Thick blood films were examined separately by 2 trained microscopists by counting at least 200 white blood cells, and counts were recorded as the average of these 2 measurements. Disagreements were resolved by a third independent examination [12] .
Data Analysis
The main outcome was cord Hb concentration (g/dL) at delivery, with a secondary outcome of fetal anemia, defined as cord Hb <12.5 g/dL, which is 2 standard deviations below the mean cord Hb in developed countries [14] . Low cord Hb was defined as cord Hb <14 g/dL for sensitivity analyses. Exposures included maternal peripheral parasitemia, placental parasitemia, and cord parasitemia, measured by detection of parasites at delivery in the mothers' peripheral, placental, and cord blood respectively. Parasitemia levels were reported in categories of <1000, 1000-9999, 10 000-99 999, and ≥100 000 parasites/µL patient blood. Malaria at delivery was defined as >1 positive blood films ( peripheral, placental, or cord) at delivery. Intermittent preventive treatment during pregnancy was originally defined as the number of SP doses taken during pregnancy (0, 1, 2, >3 doses) but was dichotomized at >1 doses vs no doses based on the constancy of effect for 1, 2, and >3 doses. Gravidity was dichotomized as primigravidae (first pregnancy) or multigravidae (second or higher pregnancy). There were no significant differences between women in their second pregnancy and women in their third or higher pregnancy. Year of enrollment was modeled using a restricted quadratic spline with 3 knots [15] . The rainy season was defined from November to April and the nonrainy season from May to October. Area of residence was reported as either urban or rural, and bed net use indicates the woman usually slept under a bed net during pregnancy. Maternal anemia was defined as maternal Hb <11 g/dL, preterm birth was defined as <37 weeks of gestation, and low birth weight was defined as <2500 g.
The variables bed net use and area of residence had a high proportion of missing data, 23.4% (n = 902) and 14.4% (n = 556), respectively. The majority of missing records were from subjects who enrolled early in the study, and these individuals were substantially different from those without missing data. In general, they used bed nets less frequently, took fewer doses of SP, delivered in the rainy season more often, and had a higher prevalence of both malaria and fetal anemia at delivery. Complete case analysis led to biased results because the proportion of missing observations is high and they are not missing completely at random.
We used IVEware, a SAS callable software application, to perform multiple imputation for missing covariates using the sequential regression imputation method [16] . Briefly, this method performs a sequence of multiple regressions for each variable with missing data. The models include all other observed variables as covariates to contribute to predictions of the imputed values. Ten iterations were performed for each imputation, and the process was repeated to create 10 complete data sets. After imputation, the prevalence of bed net use was reduced from 43.8% to 36.7% as expected because most missing individuals enrolled early in the study when bed net use was less common.
We used unconditional multivariable linear and logistic regression models to assess the associations between the prevalence of malaria at birth and cord Hb concentration and fetal anemia, respectively. Gravidity and IPTp were included in the model as effect measure modifiers and were explored in interaction terms with malaria. Year of enrollment, maternal age, season of delivery, area of residence, and bed net use were considered potential confounders of the malaria-fetal anemia relationship. Maternal anemia, low birth weight, and preterm birth were not assessed as confounders because they are likely part of the causal pathway between malaria and fetal anemia. Confounders were assessed by causal diagram and univariate associations with the exposure and outcome. Covariates were dropped from the model by backwards elimination if the parameter estimates for the main exposure changed by <10%. Only year of enrollment and season of delivery were retained as confounders in the model. Year adjusts for the changing level of malaria transmission and distribution of preventive measures over the 9-year study period [12] . Season of delivery has been considered a confounder and also adjusted for in previous studies [7, 17] . Data were analyzed using SAS version 9.2.2.
RESULTS
Of 8131 women enrolled in the parent study over the 9-year period of study, 3848 women had cord Hb measurements, met the inclusion criteria, and were considered in the present analysis. The average cord Hb concentration in the study population was 15.2 g/dL (standard deviation [SD], 2.1 g/dL), and the overall prevalence of fetal anemia was 7.9% (n = 304). The prevalence of peripheral, placental, and cord malaria at delivery was 11.9% (n = 458), 13.4% (n = 516), and 1.1% (n = 42), respectively. Level of enrollment varied over the study period, with only 1 woman enrolling at the end of 1997 and a peak of enrollment in 2005 (n = 771). Enrollment dropped heavily in 2001 due to the diversion of resources to another study [12] . The majority of study participants (n = 3325; 86.4%) received >1 doses of SP during pregnancy (Table 1 ). More than half of participants received at least 2 doses, as recommended by the WHO (n = 2021; 52.5%). Almost half of participants were primigravidae (n = 1838; 47.8%). Maternal hemoglobin concentration was normally distributed with a mean of 12.0 g/dL (SD, 1.9 g/dL).
Effects of Malaria at Delivery
Malaria parasitemia at delivery ( peripheral, placental, or cord) was crudely associated with a decrease in cord Hb of (Table 2) . Both gravidity and IPTp modified the effect of malaria, as demonstrated by the larger magnitudes of effect among primigravidae compared with multigravidae and among women who did not take SP during pregnancy compared with women who took at least 1 dose (Table 2 ). Malaria had the largest effect on fetal anemia among primigravidae who did not take SP during pregnancy, with an adjusted POR of 3.37 (95% CI, 1.68-6.78). Conversely, there was no significant effect among multigravidae who took SP during pregnancy (POR, 0.88; 95% CI, .56-1.39), and there were intermediate effects for primigravidae who took SP (POR, 1.71; 95% CI, 1.13-2.58) and multigravidae who did not take SP (POR, 1.74; 95% CI, .84-3.58). These results were reproduced in the associations between malaria and cord Hb, with a decrease of 0.64 g/dL (95% CI, .19-1.08) among primigravidae who did not take SP during pregnancy vs a decrease of only 0.08 g/dL (95% CI, −.20 to .35) among multigravidae who took SP during pregnancy.
These estimates were supported by a sensitivity analysis with the alternative outcome of low cord Hb (<14 g/dL). The crude POR for low cord Hb and any malaria at delivery was 1.55 (95% CI, 1.28-1.86). Adjusted for SP use, gravidity, year, and season of delivery, the POR was 1.38 (95% CI, 1.13-1.67). Modification of this relationship by SP use was consistent with the analyses of fetal anemia, although modification by gravidity was not as strong (data not shown). The effects of malaria on decreased cord Hb and increased odds of fetal anemia were consistent for placental, peripheral, and cord malaria individually (Table 3) . Infants of women with both placental and peripheral malaria were at highest risk for decreased cord Hb and fetal anemia compared with infants of all other women in the study.
Dose Response
The decrease in cord Hb associated with malaria at delivery increased in magnitude with increasing parasitemia (Table 4) . This trend was present for both placental and peripheral parasitemia, with an estimated decrease of 0.33 g/dL (95% CI, .14-.53) in cord Hb per log increase in placental parasitemia and a decrease of 0.35 g/dL (95% CI, .13-.57) in cord Hb per log increase in peripheral parasitemia. Similarly, the odds of fetal anemia increased significantly per log increase in both placental and peripheral parasitemia. There were not enough women with cord blood parasitemia to estimate a dose response trend.
Association With Other Birth Outcomes
In univariate analyses, decreased cord Hb and fetal anemia were strongly associated with other poor birth outcomes, such as low birth weight, preterm birth, and maternal anemia ( Table 5) . Infants of women with maternal anemia (<11 g/dL) had on average 0.87 g/dL (95% CI, .72-1.02) lower cord Hb concentration and increased odds ratio of fetal anemia compared with infants of mothers without maternal anemia. Similarly, cord Hb was lower and the odds of fetal anemia were higher among low birth weight infants and preterm births.
Effects of IPTp With SP
We did not detect a significant association between IPTp with SP and decreased cord Hb or increased odds of fetal anemia. There was no crude association between taking >1 doses of SP during pregnancy and cord Hb concentration (β, 0.07; 95% CI, −.13 to .26). Similarly, the crude prevalence odds of fetal anemia among infants of women who took >1 doses of SP during pregnancy were approximately equal to those among infants of women who did not take SP during pregnancy (POR, 0.98; 95% CI, .70-1.37). Estimates stratified by number of SP doses and adjusted for year of enrollment, gravidity, and season of delivery were close to the null, with a slight trend toward decreased odds of fetal anemia at higher doses of SP (Table 6 ). Variations over the study period in the relationship between IPTp and fetal anemia by year of enrollment were not consistent with the hypothesis that the risk of fetal anemia increased as SP resistance developed in Malawi. 
DISCUSSION
Malaria at delivery among pregnant women in Malawi was associated with decreased cord Hb and increased odds of fetal anemia in this large retrospective study. The effects were greater among primigravidae and women who did not take IPTp during pregnancy. Primigravidae do not have immunity to placental malaria, and susceptibility to fetal anemia corresponds with their increased risk for other poor birth outcomes [2] . Because parasitemia was measured only at delivery, modification by IPTp may indicate that among women with malaria at delivery, those who took IPTp were protected earlier in pregnancy and had reduced total parasitemia. Because infants of women with both placental and peripheral malaria were at highest risk for fetal anemia and there was an increasing dose response trend with parasite density, our results suggest that greater exposure to malaria parasitemia increases risk for fetal anemia and supports similar evidence from previous studies in Malawi [5, 7] . Our results do not replicate the associations between SP use during pregnancy and decreased cord Hb or increased odds of fetal anemia as previously described [13] . We did not find evidence that SP is harmful in Malawi, and we support previous observations that SP remains safe despite the development of SP resistance in the region [18] . A recent study in Ghana also did not find evidence consistent with the hypotheses that SP suppresses hematopoiesis or causes drug-based folic acid antagonism. Instead, IPTp with SP was associated with increased cord Hb and reduced fetal anemia in primigravidae, especially in conjunction with bed net use [17] .
This study is limited by cross-sectional assessment of parasitemia. Parasitemia at delivery serves as a proxy for total malaria exposure during the course of pregnancy, and we were unable to assess differences in length and intensity of parasitemia during pregnancy. In addition, the ecology of malaria in Malawi evolved over the 9-year study period during which the women were enrolled between 1997 and 2006. Malaria prevalence at delivery decreased as control tools such as IPTp and bed nets became more available, and the baseline prevalence of fetal anemia decreased from a peak of 11.5% in 1999 to 3.8% in 2006. Because factors including transmission intensity and SP resistance changed over the study period, our results may be influenced in part by these complicated period effects.
Our results may also be biased due to unmeasured confounding by covariates that may affect the risk of both malaria and fetal anemia. These variables, including socioeconomic status and nutritional status of the mother, hemoglobinopathies, human immunodeficiency virus serostatus, and infant sex, were unmeasured and not adjusted for in these analyses. Maternal anemia is likely part of the causal pathway between malaria and Abbreviations: CI, confidence interval; Hb, hemoglobin; OR, odds ratio; SD, standard deviation; SP, sulfadoxine-pyrimethamine. a Average number over 10 imputed data sets.
b Adjusted for year, gravidity, and season of delivery.
fetal anemia and was appropriately not adjusted for in these analyses. However, maternal anemia due to nutritional deficiencies and other determinants were not accounted for.
Although several covariates had a large proportion of missing data, these observations were appropriately handled by multiple imputation. The imputation had little impact on the final analyses because the covariates with the largest amounts of missing data, bed net use and area of residence, were dropped from the final adjusted model because they did not confound the relationship between malaria and fetal anemia.
In addition to its effects on maternal anemia and low birth weight, malaria during pregnancy may contribute to infant morbidity and mortality through fetal anemia. Intermittent preventive treatment during pregnancy with SP may still be an important control measure in Malawi because our study does not support evidence that SP causes fetal anemia. However, as malaria incidence continues to decrease in this area, alternative prevention methods for malaria during pregnancy, such as intermittent screening and treatment, should be explored and may prove more appropriate.
Notes
